×
-0.00698438783894816 -0.00698438783894816 -0.00698438783894816 -0.00698438783894816 -0.00698438783894816 -0.00698438783894816 -0.00698438783894816 -0.00287592440427281
Stockreport

ABLYNX ANNOUNCES POSITIVE DATA FROM ITS JAPANESE ETHNO-BRIDGING STUDY OF CAPLACIZUMAB

ABLYNX NV ADS (ABLX)  More Company Research Source: GlobeNewswire
US:NASDAQ Investor Relations: ablynx.com/investors/overview
PDF Comparable pharmacokinetics (PK) observed in Japanese and Caucasian healthy volunteers Caplacizumab was well-tolerated in all groups GHENT, Belgium, 21 December 2017 - Ablynx NV [Euronext Brussels and Nasdaq: ABLX] today announced that the single and multiple dose Phase I study demonstrated comparable PK of caplacizumab in Japanese and Caucasian subjects. Caplacizumab is the Company's wholly-owned anti-von Willebrand factor (vWF) Nanobody® being developed for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP). The Phase I single centre study enrolled 60 healthy Japanese and Caucasian subjects and consisted of single ascending dose and multiple dose parts. At all doses studied, the PK of caplacizumab in the Japanese population were similar to those observed in Caucasians. Caplacizumab was well-tolerated in all groups and its safety profile was consistent with its mechanism of action. Dr Robert K. Zeldin, Chief Medical Officer at Ablynx, commented: [Read more]

IMPACT SNAPSHOT EVENT TIME: ABLX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
ABLX alerts
from News Quantified
Opt-in for
ABLX alerts

from News Quantified
Opt-in for
ABLX alerts

from News Quantified